Alnylam gene-silencing therapy to treat kidney disorder succeeds in late-stage study

Alnylam Pharmaceuticals Inc's gene-silencing therapy for a rare kidney disorder met the main goal of a late-stage study on Tuesday, bringing the company a step closer to marketing the first approved treatment for the condition.